AI assistant
VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2021
Feb 16, 2021
29864_dirs_2021-02-16_e8843979-6910-4240-b747-d8dc4c6c1e51.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2021-02-11
Reporting Person: Parini Michael (EVP, Chief Adm, Leg & BD Off)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-02-11 | Common Stock | S | 3818 | $210.43 | Disposed | 50846 | Direct |
| 2021-02-11 | Common Stock | S | 300 | $211.21 | Disposed | 50546 | Direct |
| 2021-02-11 | Common Stock | S | 200 | $211.97 | Disposed | 50346 | Direct |
Footnotes
F1: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $210.43 (range $209.95 to $210.94).
F3: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $211.21 (range $210.97 to $211.33).
F5: Open market sales reported on this line occurred at a weighted average price of $211.97 (range $211.97 to $211.98).